pretickt

Is ZBH a good stock to buy?

Zimmer Biomet Holdings, Inc. · end-of-day data as of Nov 13, 2026

Zimmer Biomet
ZBH · $19.53B
$103.21-1.3%
Nov 13, 2026 · close
$90$100$110SepOctNov9:3016:003 months +4.4%Nov 13 · close
▲ 6
  • P/E vs sector-18.9%
  • Trendbullish
  • MAs4 of 4
  • MA20×50Golden 8d ago
  • MACD0.34
  • Sector▲ +15.9%
Neutral
  • Earnings in88d
  • P/E26.1x
  • RSI56
  • Support-0.8%
  • Resistance+3.3%
  • Off 52w high-8.3%
  • Volume1.0x
  • Bollingerupper half
  • News0.00
  • ConsensusHold · 28
  • PT$107.42 +4.1%
  • 52w range$79–$113
  • ATR+3.2%
  • Off ATH-41.0%
▼ 2
  • P/E vs own+13.2%
  • Insiders-$824K

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Zimmer Biomet a good stock to buy?

Zimmer Biomet is strong on 1 of the 5 questions about the business; weak on economics and fragility. The price is about usual: 26.1 times its earnings, near its 3-year median of 23.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage some edge
  3. Economics profits falling
  4. Execution delivers
  5. Fragility fragile
  6. Price about usual
DemandDo people want more of what it sells?steady

ZBH sales growth revenue growth

+6%a year, for the last 3 years

Zimmer Biomet's sales grew 6% a year for 3 years, to $8.23B in fiscal 2025.

ZBH analysts' forecast revenue estimates

+5%the sales they expect next fiscal year, on the last

Analysts expect Zimmer Biomet's sales to grow 5% to $8.61B in fiscal 2026 (18 analysts).

ZBH competitors

pretickt analysis+7%its sales in 12 months, on a year before

Zimmer Biomet's sales grew 7% in the 12 months to Sep 30, 2026, faster than Align Technology (+4%) and GE HealthCare (+2%), slower than Insulet (+26%) and Dexcom (+13%).

Advantage moatIs it hard to copy?some edge

ZBH margin on each sale gross margin

70%left after making the product

Zimmer Biomet kept 70% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 65%.

EconomicsDoes it make good money?profits falling

ZBH profit per share

-20%in its last fiscal year

Zimmer Biomet's earnings per share fell 20% in fiscal 2025, to $3.54.

ExecutionDoes it deliver what it promises?delivers

ZBH earnings vs estimates

8 of 8quarters above the analysts' estimate

Zimmer Biomet beat the analysts' profit estimate in each of its last 8 quarters, the latest on Nov 4, 2026.

ZBH insider selling

-$1.58Msold, net, by its executives in 12 months

Zimmer Biomet's executives and directors sold a net $1.58M of shares in the 12 months to Nov 13, 2026; none bought.

ZBH number of employees

0%about as many people as a year before

Zimmer Biomet had 17,000 employees at the end of fiscal 2025, about as many as a year before.

ZBH CEO pay

$16.11Mfor fiscal 2025, 75% of it in stock and options

Zimmer Biomet paid its CEO $16.11M for fiscal 2025, 75% of it in stock and options.

Fragility risksCould something break it?fragile

ZBH financial health Altman Z-score

2.4Altman Z-score, safe above 3

Zimmer Biomet's Altman Z-score is 2.4 (Nov 13, 2026), between 1.8 and 3, the grey zone.

ZBH in past recessions

pretickt analysis-23%its sales in the worst one

Zimmer Biomet's sales fell in each of the last 2 US recessions, by as much as 23% in fiscal 2020.

Price valuationIs the price reasonable?about usual

ZBH price vs profit P/E ratio

26.1×a year's earnings

Zimmer Biomet's P/E ratio is 26.1 (Nov 13, 2026), near its 3-year median of 23.6.

ZBH price vs competitors

pretickt analysis26.1×a year's earnings, against its competitors

Investors pay 26.1 times Zimmer Biomet's earnings (Nov 13, 2026), more than for Insulet (24.8), Align Technology (24.5) and GE HealthCare (21.7), less than for Dexcom (32.7).

ZBH analysts' target price target

+4%to their average target

Analysts' average price target for Zimmer Biomet is $107, 4% above the Nov 13, 2026 close of $103.21.

What is Zimmer Biomet's P/E ratio?

Zimmer Biomet's P/E ratio is 26.1 (Nov 13, 2026), near its 3-year median of 23.6. Investors pay 26.1 times Zimmer Biomet's earnings (Nov 13, 2026), more than for Insulet (24.8), Align Technology (24.5) and GE HealthCare (21.7), less than for Dexcom (32.7).

Who are Zimmer Biomet's biggest competitors?

pretickt compares Zimmer Biomet with Dexcom, Align Technology, Insulet and GE HealthCare. Zimmer Biomet's sales grew 7% in the 12 months to Sep 30, 2026, faster than Align Technology (+4%) and GE HealthCare (+2%), slower than Insulet (+26%) and Dexcom (+13%).

Are insiders selling Zimmer Biomet stock?

Zimmer Biomet's executives and directors sold a net $1.58M of shares in the 12 months to Nov 13, 2026; none bought.

How many employees does Zimmer Biomet have?

Zimmer Biomet had 17,000 employees at the end of fiscal 2025, about as many as a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.